SciTech Submits COVID-19 Treatment with Proven Antiviral Activity to US Health & Human Services

NanoFenretinide may offer additional support in the battle against the COVID-19 pandemic
DETROIT - April 16, 2020 - PRLog -- SciTech Development, LLC, a clinical stage specialty pharmaceutical company focused on novel, advanced drug delivery mechanisms for use with cancer therapeutics, announced it has submitted a proposal to the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Health & Human Services (HHS) for the use of its lead product, nanoFenretinide (ST-001), in the treatment of patients infected with COVID-19 (SARS-CoV-2).

SciTech's patented and differentiated delivery system, SDV, is a proprietary intravenous, phospholipid-based, nanoparticle product. Fenretinide, the first asset that SciTech is combining with SDV, is the active pharmaceutical ingredient (API) in ST-001. Of note, fenretinide has demonstrated preclinical in-vitro antiviral activity against a number of viruses including MERs, Dengue, Zika, West Nile, HIV, and HCV.

These data that fenretinide, and by inference, ST-001, shows activity in the treatment of numerous viruses supports ST-001's consideration as a repurposed drug for treating patients infected with COVID-19.  Importantly, fenretinide has been shown to inhibit viral replication in infected cells and has demonstrated modes of action that may help suppress inflammation and the progression to cytokine storms that damage vital organs.

"There are clear unmet therapeutic needs in this current pandemic," said Brian Leyland-Jones, MD, PhD Chief Medical Officer at SciTech. "All reasonable technologies, which could provide meaningful therapeutic benefits for patients infected with COVID-19, should be given an opportunity to be thoroughly and expeditiously studied, especially those with documented potential activity against the virus itself or the deleterious effects of the virus."

SciTech's drug, for proposed use against COVID-19, benefits from the following attributes:

· Early availability to the US healthcare system
· Fenretinide's demonstrated activity versus similar coronaviruses
· Readiness of large-scale, US-based production upon positive clinical evaluation of ST-001
· Broad impact of proposed clinical investigations beyond COVID-19

It is also important to note that fenretinide's extensive safety profile and unique mechanisms of action may support the use of ST-001 as monotherapy as well as in combination therapy, thereby, improving its probability of success in this setting.

About SciTech Development

SciTech Development, LLC is a clinical stage, specialty pharmaceutical, development company currently bringing to market a proven drug for diseases with otherwise limited therapeutic options. SciTech Development is headquartered in the metropolitan Detroit, Michigan area with laboratories at the Sinai Hospital BioIncubator in Baltimore Maryland.

Media and Investment Inquiries:
David Schaffer, Investor Relations
Email:*** Email Verified
Location:Detroit - Michigan - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
SciTech Development LLC News
Most Viewed
Daily News

Like PRLog?
Click to Share